|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-22
|
$406,165
|
$4,062
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
|
Cancer and Leukemia Group B
|
3U10CA031946-30S1
|
$3,449,605
|
$448,449
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Cancer and Leukemia Group B
|
5U10CA031946-30
|
$10,820,362
|
$1,406,647
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Cancer and Leukemia Group B CCOP Research Base
|
5U10CA037447-27
|
$2,389,751
|
$143,385
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Molecular pathogenesis of MLL-AF4 leukemias
|
5R01CA140575-02
|
$347,535
|
$347,535
|
ARMSTRONG, SCOTT
|
CHILDREN'S HOSPITAL BOSTON
|
|
|
RhoH GTPase in Hematopoiesis and Cancer
|
5R01CA113969-07
|
$323,678
|
$80,920
|
WILLIAMS, DAVID
|
CHILDREN'S HOSPITAL BOSTON
|
|
|
Center for Environment-Mediated Drug Resistance in Pediatric Cancer
|
1U54CA163117-01
|
$503,090
|
$251,545
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
|
Infectious origins of childhood leukemia
|
1R01CA157644-01
|
$332,000
|
$332,000
|
Muschen, Markus
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
|
Mechanism of BCL6-dependent stem cell maintenance in B cell lineage leukemia
|
5R21CA152497-02
|
$168,781
|
$168,781
|
Muschen, Markus
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
|
Targeting SYK Tyrosine Kinase to Overcome Radiation Resistance in ALL
|
1R01CA154471-01
|
$332,000
|
$332,000
|
UCKUN, FATIH
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
|
Targeting SYK Kinase in B-Lineage ALL with CD19-Specific C-61 Nanoparticles
|
5U01CA151837-02
|
$470,120
|
$470,120
|
UCKUN, FATIH
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
|
Promoting Treatment Adherence in Adolescent Leukemia
|
5R01CA119162-05
|
$606,742
|
$606,742
|
Drotar, Dennis
|
CHILDREN'S HOSPITAL MEDICAL CENTER CINCI
|
|
|
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Sy
|
1R01CA157537-01
|
$317,042
|
$317,042
|
PANG, QISHEN
|
CHILDREN'S HOSPITAL MEDICAL CENTER CINCI
|
|
|
Genetic Predictors of AML Treatment Response
|
5R01CA133881-02
|
$572,691
|
$572,691
|
Aplenc, Richard
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
|
MLL in Hematopoiesis and Leukemia in the Zebrafish Model
|
5R01CA153348-02
|
$416,334
|
$416,334
|
Felix, Carolyn
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
|
Determinants of Relapse Risk After BMT for ALL
|
5R01CA116660-05
|
$293,737
|
$293,737
|
GRUPP, STEPHAN
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
|
Delaware/Christiana Care CCOP
|
5U10CA045418-25
|
$1,147,220
|
$11,472
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
|
Cancer Center Support Grant
|
5P30CA013696-38
|
$3,816,425
|
$76,329
|
Abate-Shen, Cory
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Cancer Center Support Grant
|
3P30CA013696-38S1
|
$74,998
|
$1,500
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Cancer Center Support Grant
|
3P30CA013696-38S2
|
$139,995
|
$2,800
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
The role of PHF6 in T-cell acute lymphoblastic leukemia
|
1R01CA155743-01
|
$333,211
|
$333,211
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Mechanisms of T-Cell Leukemogenesis Induced by Notch1
|
5R01CA120196-05
|
$296,723
|
$148,362
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
The role of AKT signaling in NOTCH1 induced leukemias
|
5R01CA129382-04
|
$324,598
|
$162,299
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-46S5
|
$11,164,583
|
$223,292
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-46S6
|
$75,000
|
$1,500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Cancer and Leukemia Group B
|
5U10CA032291-30
|
$469,660
|
$61,056
|
Burstein, Harold
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Development of Novel Therapeutic Strategies in Human Leukemias
|
5P01CA066996-14
|
$2,306,268
|
$1,153,134
|
GRIFFIN, JAMES
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Zebrafish Chemical and Classical Genetics Approach to the Pathogenesis of T-ALL
|
5K08CA133103-04
|
$140,940
|
$140,940
|
Gutierrez, Alejandro
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Molecular Pathways to Thynmic Lymphoma and Leukemia
|
5P01CA109901-07
|
$2,028,518
|
$1,460,533
|
LOOK, A
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Pathway Dependence on Tyrosine Kinase TYK2 in T-cell Acute Lymphoblastic Leukemia
|
1K99CA157951-01
|
$137,700
|
$68,850
|
Sanda, Takaomi
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Validating Syk as a Target for AML Therapy
|
5R01CA140292-03
|
$352,231
|
$352,231
|
STEGMAIER, KIMBERLY
|
DANA-FARBER CANCER INSTITUTE
|
|
|
Cancer and Leukemia Group B
|
5U10CA047577-24
|
$95,798
|
$12,454
|
CRAWFORD, JEFFREY
|
DUKE UNIVERSITY
|
|
|
FitFab 4 Survivors
|
1R21CA155965-01A1
|
$209,096
|
$209,096
|
Fuemmeler, Bernard
|
DUKE UNIVERSITY
|
|
|
Duke Comp Cancer Inst. Core Support Grant
|
3P30CA014236-37S1
|
$37,988
|
$380
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
|
Duke Comp Cancer Inst. Core Support Grant
|
5P30CA014236-37
|
$5,723,821
|
$57,238
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
|
Duke Comp Cancer Inst. Core Support Grant
|
3P30CA014236-37S2
|
$75,000
|
$750
|
MEANS, ANTHONY
|
DUKE UNIVERSITY
|
|
|
MDM2 regulates XIAP gene expression in cancer treatment
|
5R01CA123490-04
|
$249,581
|
$62,395
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
|
EORTC HEADQUARTERS
|
2U10CA011488-41
|
$232,518
|
$25,577
|
SYLVESTER, RICHARD
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
|
North Shore CCOP
|
5U10CA035279-28
|
$599,459
|
$11,989
|
VINCIGUERRA, VINCENT
|
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
|
|
|
Comprehensive Cancer Center Program at Fox Chase
|
2P30CA006927-48
|
$4,038,908
|
$80,778
|
SEIDEN, MICHAEL
|
FOX CHASE CANCER CENTER
|
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-48S1
|
$50,859
|
$1,017
|
SEIDEN, MICHAEL
|
FOX CHASE CANCER CENTER
|
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-48S2
|
$74,930
|
$1,499
|
SEIDEN, MICHAEL
|
FOX CHASE CANCER CENTER
|
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-48S3
|
$140,001
|
$2,800
|
SEIDEN, MICHAEL
|
FOX CHASE CANCER CENTER
|
|
|
Comprehensive Cancer Center Program at Fox Chase
|
3P30CA006927-48S4
|
$300,000
|
$6,000
|
SEIDEN, MICHAEL
|
FOX CHASE CANCER CENTER
|
|
|
Pediaric Oncology Research Training Program
|
5T32CA009351-33
|
$177,227
|
$26,584
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Targeted therapy of ALL with gene-modified central memory T cells
|
5R01CA136551-03
|
$543,264
|
$271,632
|
Riddell, Stanley
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Cancer and Leukemia Group B
|
5U10CA077597-14
|
$87,915
|
$11,429
|
Liu, Minetta
|
GEORGETOWN UNIVERSITY
|
|
|
Hematology-Oncology Associates of Central New York CCOP
|
5U10CA045389-25
|
$706,704
|
$14,134
|
KIRSHNER, JEFFREY
|
HEMATOLOGY-ONCOLOGY ASSOCIATES/CTL NY
|
|
|
Rpl22 as Biomarker of Prognosis and Therapeutic Response in T-ALL
|
5R21CA141194-02
|
$184,076
|
$184,076
|
WIEST, DAVID
|
INSTITUTE FOR CANCER RESEARCH
|
|
|
International Symposium on Juvenile Myelomonocytic Leukemia (JMML)
|
2R13CA132568-05
|
$15,000
|
$15,000
|
Thomas, Sandra
|
JMML FOUNDATION
|
|
Total relevant funding to Childhood Leukemia for this search: $39,317,116
|
